# ARA-290 (Cibinetide): Evidence, Mechanism & Legal Status

> A clinical monograph on ARA-290 (cibinetide) — the non-erythropoietic EPO-derived peptide with genuine Phase 2 RCT data for small-fiber neuropathy, no Phase 3, and an unapproved, WADA-prohibited 2026 status.

*Published 2026-06-30 · Updated 2026-07-01 · By Elena Soto, PharmD*

The short answer
ARA-290 (cibinetide) is one of the few peptides marketed online with **genuine randomized, double-blind, placebo-controlled human data** — Phase 2 evidence of objective small-nerve-fiber regeneration in sarcoidosis and diabetic neuropathy at 4 mg subcutaneous daily, *without* raising hematocrit. That earns it **Grade B** — real human signal, but small, single-network, never advanced to Phase 3, and not approved. It is not FDA-approved (Orphan/Fast Track only), and is prohibited in sport at all times under WADA.[1](https://peptidevox.com/#r1)[3](https://peptidevox.com/#r3)[10](https://peptidevox.com/#r10)

ARA-290 (cibinetide; also called pHBSP or helix B surface peptide) is an 11-amino-acid peptide engineered from erythropoietin and developed for tissue protection and nerve repair — most credibly for small-fiber neuropathy.[1](https://peptidevox.com/#r1) Unlike most peptides circulating in recovery and longevity circles, it carries real Phase 2 trial data. This monograph separates what is proven from what is hyped.

*This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. ARA-290 is not an FDA-approved drug; it is sold as a "research chemical not for human use" and is prohibited in sport. Dosing figures are reported strictly as seen in the published literature and registered trials for completeness — not as recommendations. Consult a licensed clinician before any health decision.*

## What is ARA-290 and how does it work?

ARA-290/cibinetide is a synthetic 11-amino-acid linear peptide (sequence pyroGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser; molecular formula C51H84N16O21, MW about 1257 Da, CAS 1208243-50-8) corresponding to the aqueous-exposed face of helix B of erythropoietin.[1](https://peptidevox.com/#r1)[6](https://peptidevox.com/#r6) It was designed by Michael Brines and Anthony Cerami at Araim Pharmaceuticals.[2](https://peptidevox.com/#r2)

The mechanism is the most elegant part of the story. Erythropoietin signals through two distinct receptor systems: the classical homodimeric EPO receptor on erythroid progenitors that drives red-cell production, and the **innate repair receptor (IRR)** — a heterocomplex of the EPO receptor subunit with the beta-common receptor (CD131, the shared signaling chain of the GM-CSF, IL-3 and IL-5 receptors). ARA-290 binds the IRR with high selectivity and has negligible activity at the erythropoietic receptor, which is the mechanistic basis for its "non-erythropoietic" profile.[1](https://peptidevox.com/#r1)[2](https://peptidevox.com/#r2) Because the IRR is locally upregulated under injury, hypoxia, inflammation or metabolic stress, ARA-290 behaves as a context-restricted agonist — activating repair preferentially where the receptor is induced. Engagement triggers JAK2 phosphorylation with downstream STAT3 and PI3K-Akt signaling, upregulation of anti-apoptotic Bcl-2-family proteins, and suppression of pro-inflammatory cytokines such as TNF-alpha and IL-6, with documented modulation of macrophage and spinal microglial responses in injury models.[5](https://peptidevox.com/#r5)

Pharmacokinetically it is a peptide, not orally bioavailable, given by injection. Its plasma half-life is very short — terminal t-half of roughly 20 minutes after a 4 mg subcutaneous dose — yet a core feature is the dissociation between plasma exposure and biological duration: the peptide acts like a molecular switch, producing effects that persist far longer than its minutes-long circulating life through the downstream signaling cascade.[1](https://peptidevox.com/#r1)[2](https://peptidevox.com/#r2)

## What is the evidence by indication?

Human Phase 2 RCT evidence is real but limited: small samples, largely from a single Leiden/Araim research network, never advanced to Phase 3, no approval. The lead indications earn Grade B; the broader claims rest on animal data only (Grade C). The completed pivotal trial is registered at [ClinicalTrials.gov (NCT02039687)](https://clinicaltrials.gov/study/NCT02039687), with results posted.[4](https://peptidevox.com/#r4)

  ARA-290 evidence by indication

    IndicationBest evidenceGrade

    Sarcoidosis-associated small-fiber neuropathyPilot RCT (n=22) + pivotal dose-ranging Phase 2b RCT (n=64): objective corneal & skin nerve-fiber regeneration at 4 mg SCB (human Phase 2)
    Type 2 diabetic neuropathy (+ metabolic signal)Phase 2 RCT (n=48): symptom + small-fiber improvement, modest HbA1c/lipid signalB (human Phase 2)
    Diabetic macular edemaExploratory open-label Phase 2 (safety only; no controlled efficacy)C-to-D
    Cardiac / TBI / burn-shock / wound healing / islet transplantAnimal & in-vitro models only; EMA orphan designation for islet-transplant graft lossC (preclinical)

The sarcoidosis program is the best-evidenced and the basis for orphan designation. A single-site pilot RCT (n=22 completers; 2 mg IV thrice weekly for four weeks) showed significantly greater improvement on the Small Fiber Neuropathy Screening List versus placebo (p Proven vs hyped
Proven (Grade B): small-nerve-fiber regeneration biomarkers and symptoms improve in small Phase 2 trials at a specific 4 mg SC daily dose, without raising hematocrit. Hyped: cardiac, brain-injury, wound-healing, longevity and general "tissue-repair" claims rest on animal data only (Grade C), and the celebrated pain relief was inconsistently superior to placebo even in the positive trials.[3](https://peptidevox.com/#r3)[5](https://peptidevox.com/#r5)

## What doses appear in the literature?

Reported strictly as information, not a protocol. The most-studied regimen is 4 mg subcutaneous, self-administered once daily, for 28 days — the dose that hit objective endpoints in both the pivotal sarcoidosis Phase 2b and the diabetes RCT.[2](https://peptidevox.com/#r2)[3](https://peptidevox.com/#r3) The pivotal trial tested 1, 4 and 8 mg subcutaneous daily; efficacy followed an inverted-U curve, with 4 mg optimal and 8 mg no better — and on the primary endpoint, non-significant — so more was not better.[3](https://peptidevox.com/#r3) The earlier IV pilot used 2 mg intravenously in saline over about two minutes, thrice weekly for four weeks.[1](https://peptidevox.com/#r1) Trial material was a sterile peptide solution prepared for parenteral injection; no FDA-approved formulation, labeled concentration or sanctioned compounding pathway exists, and products sold online are unregulated and of unverified identity and purity.[1](https://peptidevox.com/#r1)[11](https://peptidevox.com/#r11)

## How safe is ARA-290?

Across the Phase 2 program, cibinetide was generally well tolerated. The IV pilot reported no adverse events.[1](https://peptidevox.com/#r1) In the diabetes RCT, adverse-event frequency was similar to placebo and predominantly mild; there were four serious adverse events in the active arm, of which two were judged possibly related (worsening borderline renal insufficiency in a patient on furosemide, prompting a stop; and a fatal myocardial infarction in a 70-year-old two weeks after the last dose, judged unrelated).[2](https://peptidevox.com/#r2) Commonly cited mild effects with subcutaneous dosing are injection-site reactions and transient headache.[12](https://peptidevox.com/#r12) A central design feature is hematologic safety: repeated dosing produced no change in hemoglobin or hematocrit in either trial, confirming the non-erythropoietic profile and, by design, avoiding EPO's thrombosis, hypertension and viscosity risks.[1](https://peptidevox.com/#r1)[2](https://peptidevox.com/#r2)

The theoretical risks are mechanistic. As an EPO-pathway agonist that promotes angiogenesis and anti-apoptotic signaling in repair models, ARA-290 raises a precautionary concern about supporting tumor angiogenesis, so caution is warranted in active malignancy — though no human tumor-promotion signal has been demonstrated.[13](https://peptidevox.com/#r13) Repeated dosing of a synthetic peptide can elicit anti-drug antibodies; the diabetes trial measured these and found them negative at day 28, but longer-term immunogenicity is unestablished.[2](https://peptidevox.com/#r2) Long-term safety beyond four-to-eight-week exposures is simply not characterized. Precautionary or contraindicated populations include pregnancy or lactation, active or suspected malignancy, severe renal impairment, and athletes subject to anti-doping testing; trials excluded BMI above 34 and capped age around 65-70.[1](https://peptidevox.com/#r1)[2](https://peptidevox.com/#r2)

## What is the FDA and WADA status in 2026?

ARA-290/cibinetide is not FDA-approved for any indication and remains investigational. It holds FDA Orphan Drug Designation for sarcoidosis (granted July 5, 2016) and a separate Orphan Drug plus Fast Track designation for neuropathic pain in sarcoidosis.[7](https://peptidevox.com/#r7)[9](https://peptidevox.com/#r9) Critically, orphan and Fast Track designations *support* development — seven-year exclusivity, fee waivers, expedited review channels — but they are **not** marketing approval. No NDA or BLA was filed; the developer, Araim Pharmaceuticals, reportedly ceased operations, and there is no active sponsor IND, leaving no legal compounding pathway and no licensed prescriber access in the US.[12](https://peptidevox.com/#r12)[14](https://peptidevox.com/#r14) The EMA granted orphan designation for sarcoidosis and, separately, for prevention of graft loss in pancreatic islet transplantation, but it is not approved or marketed in any EU member state.[8](https://peptidevox.com/#r8) Material sold online as ARA-290 is an unregulated research chemical of unverified identity, purity and dose.[11](https://peptidevox.com/#r11)

For athletes the picture is unambiguous. The 2026 WADA Prohibited List bans, under S2.1 (erythropoietins and agents affecting erythropoiesis), both EPO-mimetic agents and an explicit category of innate repair receptor agonists.[10](https://peptidevox.com/#r10) As an IRR agonist and EPO-derived peptide, cibinetide falls squarely within S2 and is prohibited at all times, both in and out of competition; being unapproved, it is additionally captured by S0 (non-approved substances), with no Therapeutic Use Exemption pathway.[11](https://peptidevox.com/#r11) Any WADA-tested athlete should treat ARA-290 as banned.

**Bottom line.** ARA-290 is one of the more legitimately clinically-advanced non-hematopoietic EPO-analog peptides: a clean, well-defined mechanism plus real randomized, double-blind, placebo-controlled Phase 2 data in two indications, with objective evidence of small-nerve-fiber regeneration at 4 mg subcutaneous daily. That earns it Grade B. What is proven is narrow and provisional; what is hyped — cardiac, brain, wound-healing and longevity claims — rests on animal data only. Key uncertainties remain: no Phase 3, near-total reliance on a single research network, tiny samples, no long-term safety, and a dormant developer. Regulatory reality in 2026: not FDA-approved, EMA orphan but unapproved, WADA-prohibited, and sold only as an unregulated research chemical. A scientifically credible, mechanistically elegant Phase 2 asset whose human promise is genuine but unconfirmed — not an approved therapy. The 2026 WADA listing should be re-verified against the live list before any competition reliance.

---
Source: https://peptidevox.com/peptide-encyclopedia/ara-290
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt